We're logging you in...
Saved successfully!

Helio Vision

Helio Vision develops a therapy for rare, fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery.
CLAIMED
FUNDRAISING
Request Introduction
Company was reported as not operating anymore on Apr 02, 2020
Helio Vision was founded in 2016 to develop a therapy for rare, fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The co-founders of Helio Vision, Massachusetts Eye and Ear Infirmary physicians Drs. Dean Eliott and Tomasz Stryjewski, have discovered that by using sustained intravitreal exposure to methotrexate, a medication with anti-proliferative and anti-inflammatory properties, this dreaded post-operative scarring cycle may be prevented. ​
Industries
Biotechnology, Clinical Trials, Travel
Location
Lexington, Massachusetts, United States
Founded
2016
Employees
Stage
M&A
Social
Acquired By
Aldeyra Therapeutics

Funding

🔥 Helio Vision is looking for new investment opportunities.
Request introduction if you're interested.
259504
Total funding
Investors
1
Number of rounds
Top investors
Last Funding Type
Seed

Team

Founders
Dean Eliott, Josef H. von Rickenbach, Tomasz Stryjewski
🔓 Owner Login / Claim Ownership